227 related articles for article (PubMed ID: 30266329)
1. Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 randomised, controlled, non-inferiority trial.
Pitisuttithum P; Chokephaibulkit K; Sirivichayakul C; Sricharoenchai S; Dhitavat J; Pitisuthitham A; Phongsamart W; Boonnak K; Lapphra K; Sabmee Y; Wittawatmongkol O; Chauhan M; Wijagkanalan W; Hommalai G; Fortuna L; Chinwangso P; Poredi IK; van den Biggelaar AHJ; Pham HT; Viviani S
Lancet Infect Dis; 2018 Nov; 18(11):1260-1268. PubMed ID: 30266329
[TBL] [Abstract][Full Text] [Related]
2. A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial.
Sricharoenchai S; Sirivichayakul C; Chokephaibulkit K; Pitisuttithum P; Dhitavat J; Pitisuthitham A; Phongsamart W; Boonnak K; Lapphra K; Sabmee Y; Wittawatmongkol O; Chinwangso P; Poredi IK; Petre J; Thai PH; Viviani S
Lancet Infect Dis; 2018 Jan; 18(1):58-67. PubMed ID: 29066131
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.
Sirivichayakul C; Chanthavanich P; Limkittikul K; Siegrist CA; Wijagkanalan W; Chinwangso P; Petre J; Hong Thai P; Chauhan M; Viviani S
Hum Vaccin Immunother; 2017 Jan; 13(1):136-143. PubMed ID: 27686283
[TBL] [Abstract][Full Text] [Related]
4. A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women.
Puthanakit T; Chokephaibulkit K; Chaithongwongwatthana S; Bhat N; Tang Y; Anugulruengkitt S; Chayachinda C; Anuwutnavin S; Lapphra K; Rungmaitree S; Tawan M; Andi-Lolo I; Holt R; Fortuna L; Kerdsomboon C; Yuwaree V; Mansouri S; Thai PH; Innis BL
Vaccine; 2023 Jul; 41(31):4541-4553. PubMed ID: 37330371
[TBL] [Abstract][Full Text] [Related]
5. Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial.
Blanchard Rohner G; Chatzis O; Chinwangso P; Rohr M; Grillet S; Salomon C; Lemaître B; Boonrak P; Lawpoolsri S; Clutterbuck E; Poredi IK; Wijagkanalan W; Spiegel J; Pham HT; Viviani S; Siegrist CA
Clin Infect Dis; 2019 Mar; 68(7):1213-1222. PubMed ID: 30759183
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age.
Chokephaibulkit K; Puthanakit T; Bhat N; Mansouri S; Tang Y; Lapphra K; Rungmaitree S; Anugulruengkitt S; Jantarabenjakul W; Andi-Lolo I; Holt R; Fortuna L; Kerdsomboon C; Chinwangso P; Suwitruengrit L; van den Biggelaar AHJ; Viviani S; Pham HT; Innis BL
Vaccine; 2022 Apr; 40(15):2352-2361. PubMed ID: 34789403
[TBL] [Abstract][Full Text] [Related]
7. A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults.
Leroux-Roels G; Lattanzi M; Solis CD; Contorni M; Costantini M; Moraschini L; Bardelli M; Bertholet S; Borgogni E; Buricchi F; Cantisani R; Faenzi E; Finco O; Leuzzi R; Pizza M; Rosa D; Schiavetti F; Seubert A; Spensieri F; Volpini G; Zedda L; Giudice GD; Galgani I
Hum Vaccin Immunother; 2018 Jan; 14(1):45-58. PubMed ID: 29172945
[TBL] [Abstract][Full Text] [Related]
8. Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccines.
Chokephaibulkit K; Puthanakit T; Chaithongwongwatthana S; Bhat N; Tang Y; Anugulruengkitt S; Chayachinda C; Anuwutnavin S; Lapphra K; Rungmaitree S; Tawan M; Andi-Lolo I; Holt R; Fortuna L; Kerdsomboon C; Yuwaree V; Mansouri S; Thai PH; Innis BL
Vaccine; 2024 Jan; 42(2):383-395. PubMed ID: 38061956
[TBL] [Abstract][Full Text] [Related]
9. Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aP
Pitisuttithum P; Dhitavat J; Sirivichayakul C; Pitisuthitham A; Sabmee Y; Chinwangso P; Kerdsomboon C; Fortuna L; Spiegel J; Chauhan M; Poredi IK; van den Biggelaar AHJ; Wijagkanalan W; Viviani S; Mansouri S; Pham HT
EClinicalMedicine; 2021 Jul; 37():100976. PubMed ID: 34386749
[TBL] [Abstract][Full Text] [Related]
10. Maternal pertussis vaccination and its effects on the immune response of infants aged up to 12 months in the Netherlands: an open-label, parallel, randomised controlled trial.
Barug D; Pronk I; van Houten MA; Versteegh FGA; Knol MJ; van de Kassteele J; Berbers GAM; Sanders EAM; Rots NY
Lancet Infect Dis; 2019 Apr; 19(4):392-401. PubMed ID: 30938299
[TBL] [Abstract][Full Text] [Related]
11. Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults.
Halperin SA; Smith B; Russell M; Scheifele D; Mills E; Hasselback P; Pim C; Meekison W; Parker R; Lavigne P; Barreto L
Pediatr Infect Dis J; 2000 Apr; 19(4):276-83. PubMed ID: 10783014
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study.
Rivera L; Schwarz TF; Kim KH; Kim YK; Behre U; Cha SH; Jo DS; Lee J; Lee JS; Cheuvart B; Jastorff A; Van der Wielen M
Vaccine; 2018 Jul; 36(31):4750-4758. PubMed ID: 29960800
[TBL] [Abstract][Full Text] [Related]
13. Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults--a review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience.
Thierry-Carstensen B; Dalby T; Stevner MA; Robbins JB; Schneerson R; Trollfors B
Vaccine; 2013 Oct; 31(45):5178-91. PubMed ID: 23994021
[TBL] [Abstract][Full Text] [Related]
14. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and Safety of Monovalent Acellular Pertussis Vaccine at Birth: A Randomized Clinical Trial.
Wood N; Nolan T; Marshall H; Richmond P; Gibbs E; Perrett K; McIntyre P
JAMA Pediatr; 2018 Nov; 172(11):1045-1052. PubMed ID: 30208475
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged ≥60 years: an open-label, randomised trial.
Zimmermann U; Gavazzi G; Richard P; Eymin C; Soubeyrand B; Baudin M
Vaccine; 2013 Mar; 31(11):1496-502. PubMed ID: 23313654
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
[TBL] [Abstract][Full Text] [Related]
18. Long-term immunogenicity of a single dose of acellular pertussis vaccine in paediatric health-care workers.
Littmann M; Hülsse C; Riffelmann M; Wirsing von König CH
Vaccine; 2008 May; 26(19):2344-9. PubMed ID: 18396360
[TBL] [Abstract][Full Text] [Related]
19. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine compared to standard-dose diphtheria, tetanus, acellular pertussis when used as a pre-school booster in UK children: A 5-year follow-up of a randomised controlled study.
John T; Voysey M; Yu LM; McCarthy N; Baudin M; Richard P; Fiquet A; Kitchin N; Pollard AJ
Vaccine; 2015 Aug; 33(36):4579-85. PubMed ID: 26165918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
